An Uncontrolled, Open-label Feasibility Study to Demonstrate That a GnRH Agonist (Decapeptyl) Can be Safely Administered to Trigger Final Oocyte Maturation in High Responder Patients to Mitigate the Risk of OHSS
Latest Information Update: 12 May 2022
At a glance
- Drugs Triptorelin (Primary)
- Indications Ovarian hyperstimulation syndrome
- Focus Adverse reactions
- 23 Jan 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov
- 21 Nov 2012 New trial record